• "Transforming standards of patient care: reimagining medicine, drug-hunting, and market access."

    Vas Narasimhan is not your typical CEO, having started his career in public health, where he became passionate about how to impact health on a large scale. Now, many years later and a little over a year into his role as CEO of Novartis, his passion remains undiminished. The impact the company is having on patients is remarkable, be it with “miraculous” treatments that cure children of deadly diseases with one pill, or with the Novartis Access program.

    In the first half of my interview with Vas, we discuss what Reimagining Medicine means in an R&D based company that is deeply committed to innovation; addressing the needs of the 2 billion people with no access to health care; and the potential for, and challenges of, radically improving patient outcomes with advanced therapies.

    #Innovation #reimaginemedicine #VasNarasimhan

    Link here to the full article on our website: outsidelens.com/ep2
    "Transforming standards of patient care: reimagining medicine, drug-hunting, and market access." Vas Narasimhan is not your typical CEO, having started his career in public health, where he became passionate about how to impact health on a large scale. Now, many years later and a little over a year into his role as CEO of Novartis, his passion remains undiminished. The impact the company is having on patients is remarkable, be it with “miraculous” treatments that cure children of deadly diseases with one pill, or with the Novartis Access program. In the first half of my interview with Vas, we discuss what Reimagining Medicine means in an R&D based company that is deeply committed to innovation; addressing the needs of the 2 billion people with no access to health care; and the potential for, and challenges of, radically improving patient outcomes with advanced therapies. #Innovation #reimaginemedicine #VasNarasimhan Link here to the full article on our website: outsidelens.com/ep2
    Like
    Love
    18
    1 Comments 0 Shares 297 Views